推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
溶解性
DMSO: >10 mg/mL
创始人
Daiichi-Sankyo
储存温度
room temp
SMILES字符串
CC(C)OC(=O)C1=C(C)NC(N)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC3CN(C3)C(c4ccccc4)c5ccccc5
InChI
1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
InChI key
ZKFQEACEUNWPMT-UHFFFAOYSA-N
应用
Azelnidipine is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis.
生化/生理作用
Azelnidipine, a novel dihydropyridine derivative, is a L-type calcium channel blocker and antihypertensive. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.
特点和优势
This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Daiichi-Sankyo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语:
Danger
危险声明
危险分类
Acute Tox. 4 Oral - Eye Dam. 1
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
American journal of hypertension, 25(8), 862-868 (2012-06-01)
We aimed to investigate the association of the change in the ambulatory arterial stiffness index (AASI) with that in carotid-femoral pulse wave velocity (cfPWV) during treatment with antihypertensive medication. We enrolled 207 hypertensive patients treated with olmesartan monotherapy for 12
Hypertension (Dallas, Tex. : 1979), 59(6), 1132-1138 (2012-05-02)
Day-by-day home blood pressure (BP) variability (BPV) was reported to be associated with increased cardiovascular risk. We aimed to test the hypothesis that the angiotensin II receptor blocker/calcium-channel blocker combination decreases day-by-day BPV more than the angiotensin II receptor blocker/diuretic
Vascular health and risk management, 7, 383-390 (2011-07-29)
The aim of this study was to compare the effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients. Patients with brachial systolic BP ≥ 140 mmHg
Journal of nephrology, 25(5), 699-708 (2011-10-25)
In the present investigation we extracted data on hypertensive patients with chronic kidney disease (CKD) who were enrolled in 3 studies - 2 studies of the angiotensin receptor blocker (ARB) olmesartan medoxomil (OLM), lasting 12 weeks and 2 years, respectively
Hypertension in older adults: progress and limitations.
The American journal of medicine, 125(10), 949-950 (2012-08-21)
商品
We offers many products related to calcium channels for your research needs.
我们提供多种与钙通道相关的产品以满足您的各类研究需求。
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门